136 related articles for article (PubMed ID: 37906593)
1. Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers.
Qiu H; Li G; Yuan J; Yang D; Ma Y; Wang F; Dai Y; Chang X
Cell Rep; 2023 Nov; 42(11):113340. PubMed ID: 37906593
[TBL] [Abstract][Full Text] [Related]
2. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
3. Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.
Tran VK; Takeshima Y; Zhang Z; Yagi M; Nishiyama A; Habara Y; Matsuo M
J Med Genet; 2006 Dec; 43(12):924-30. PubMed ID: 16738009
[TBL] [Abstract][Full Text] [Related]
4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
6. Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping.
Incitti T; De Angelis FG; Cazzella V; Sthandier O; Pinnarò C; Legnini I; Bozzoni I
Mol Ther; 2010 Sep; 18(9):1675-82. PubMed ID: 20551908
[TBL] [Abstract][Full Text] [Related]
7. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
8. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.
Long C; Li H; Tiburcy M; Rodriguez-Caycedo C; Kyrychenko V; Zhou H; Zhang Y; Min YL; Shelton JM; Mammen PPA; Liaw NY; Zimmermann WH; Bassel-Duby R; Schneider JW; Olson EN
Sci Adv; 2018 Jan; 4(1):eaap9004. PubMed ID: 29404407
[TBL] [Abstract][Full Text] [Related]
9. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
10. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
11. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
13. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
[TBL] [Abstract][Full Text] [Related]
14. Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene.
Greer K; Johnsen R; Nevo Y; Fellig Y; Fletcher S; Wilton SD
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630425
[TBL] [Abstract][Full Text] [Related]
15. Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudo-exon responsible for x-linked dilated cardiomyopathy.
Rimessi P; Fabris M; Bovolenta M; Bassi E; Falzarano S; Gualandi F; Rapezzi C; Coccolo F; Perrone D; Medici A; Ferlini A
Hum Gene Ther; 2010 Sep; 21(9):1137-46. PubMed ID: 20486769
[TBL] [Abstract][Full Text] [Related]
16. Restoring Dystrophin Expression with Duchenne Muscular Dystrophy Exon 45 Skipping in Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Sato M; Shiba N; Miyazaki D; Shiba Y; Nakamura A
Methods Mol Biol; 2023; 2587():141-151. PubMed ID: 36401028
[TBL] [Abstract][Full Text] [Related]
17. Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping.
Wang P; Li H; Zhu M; Han RY; Guo S; Han R
Mol Ther Methods Clin Dev; 2023 Mar; 28():40-50. PubMed ID: 36588820
[TBL] [Abstract][Full Text] [Related]
18. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
19. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
20. Categorization of 77 dystrophin exons into 5 groups by a decision tree using indexes of splicing regulatory factors as decision markers.
Malueka RG; Takaoka Y; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
BMC Genet; 2012 Mar; 13():23. PubMed ID: 22462762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
